Literature DB >> 29061560

Bitter Melon Prevents the Development of 4-NQO-Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling.

Subhayan Sur1, Robert Steele1, Rajeev Aurora2, Mark Varvares3, Katherine E Schwetye1, Ratna B Ray4,3.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and tobacco is one of the most common factors for HNSCC of the oral cavity. We have previously observed that bitter melon (Momordica charantia) extract (BME) exerts antiproliferative activity against several cancers including HNSCC. In this study, we investigated the preventive role of BME in 4-nitroquinoline 1-oxide (4-NQO) carcinogen-induced HNSCC. We observed that BME feeding significantly reduced the incidence of 4-NQO-induced oral cancer in a mouse model. Histologic analysis suggested control 4-NQO-treated mouse tongues showed neoplastic changes ranging from moderate dysplasia to invasive squamous cell carcinoma, whereas no significant dysplasia was observed in the BME-fed mouse tongues. We also examined the global transcriptome changes in normal versus carcinogen-induced tongue cancer tissues, and following BME feeding. Gene ontology and pathway analyses revealed a signature of biological processes including "immune system process" that is significantly dysregulated in 4-NQO-induced oral cancer. We identified elevated expression of proinflammatory genes, s100a9, IL23a, IL1β and immune checkpoint gene PDCD1/PD1, during oral cancer development. Interestingly, BME treatment significantly reduced their expression. Enhancement of MMP9 ("ossification" pathway) was noted during carcinogenesis, which was reduced in BME-fed mouse tongue tissues. Our study demonstrates the preventive effect of BME in 4-NQO-induced carcinogenesis. Identification of pathways involved in carcinogen-induced oral cancer provides useful information for prevention strategies. Together, our data strongly suggest the potential clinical benefits of BME as a chemopreventive agent in the control or delay of carcinogen-induced HNSCC development and progression. Cancer Prev Res; 11(4); 191-202. ©2017 AACRSee related editorial by Rao, p. 185. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29061560      PMCID: PMC5882513          DOI: 10.1158/1940-6207.CAPR-17-0237

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  34 in total

1.  Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis.

Authors:  Ratna B Ray; Amit Raychoudhuri; Robert Steele; Pratibha Nerurkar
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

Review 3.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

5.  Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells.

Authors:  Manjinder Kaur; Gagan Deep; Anil K Jain; Komal Raina; Chapla Agarwal; Michael F Wempe; Rajesh Agarwal
Journal:  Carcinogenesis       Date:  2013-03-08       Impact factor: 4.944

6.  Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.

Authors:  Julie E Bauman; Yan Zang; Malabika Sen; Changyou Li; Lin Wang; Patricia A Egner; Jed W Fahey; Daniel P Normolle; Jennifer R Grandis; Thomas W Kensler; Daniel E Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2016-06-23

7.  Enhancement of active MMP release and invasive activity of lymph node metastatic tongue cancer cells by elevated signaling via the TNF-α-TNFR1-NF-κB pathway and a possible involvement of angiopoietin-like 4 in lung metastasis.

Authors:  Takuya Tanaka; Takahisa Imamura; Masakazu Yoneda; Atsushi Irie; Hidenao Ogi; Masashi Nagata; Ryoji Yoshida; Daiki Fukuma; Kenta Kawahara; Masanori Shinohara; Hideki Nakayama
Journal:  Int J Oncol       Date:  2016-08-10       Impact factor: 5.650

8.  The molecular features of tongue epithelium treated with the carcinogen 4-nitroquinoline-1-oxide and alcohol as a model for HNSCC.

Authors:  Kwame Osei-Sarfo; Xiao-Han Tang; Alison M Urvalek; Theresa Scognamiglio; Lorraine J Gudas
Journal:  Carcinogenesis       Date:  2013-06-19       Impact factor: 4.944

9.  Black raspberries in cancer clinical trials: Past, present and future.

Authors:  Laura A Kresty; Susan R Mallery; Gary D Stoner
Journal:  J Berry Res       Date:  2016       Impact factor: 2.352

10.  Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.

Authors:  Ananthi Rajamoorthi; Shubham Shrivastava; Robert Steele; Pratibha Nerurkar; Juan G Gonzalez; Susan Crawford; Mark Varvares; Ratna B Ray
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more
  9 in total

1.  Bioactivity-Guided Isolation of Neuritogenic Factor from the Seeds of the Gac Plant (Momordica cochinchinensis).

Authors:  E Mazzio; R Badisa; S Eyunni; S Ablordeppey; B George; K F A Soliman
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-31       Impact factor: 2.629

Review 2.  Developments in Taste-Masking Techniques for Traditional Chinese Medicines.

Authors:  Xiao Zheng; Fei Wu; Yanlong Hong; Lan Shen; Xiao Lin; Yi Feng
Journal:  Pharmaceutics       Date:  2018-09-12       Impact factor: 6.321

3.  Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract.

Authors:  Subhayan Sur; Hiroshi Nakanishi; Colin Flaveny; Joseph E Ippolito; Jane McHowat; David A Ford; Ratna B Ray
Journal:  Cell Commun Signal       Date:  2019-10-21       Impact factor: 5.712

Review 4.  Bitter Melon (Momordica Charantia), a Nutraceutical Approach for Cancer Prevention and Therapy.

Authors:  Subhayan Sur; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

5.  Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.

Authors:  Meng Yang; Qingqiong Luo; Xu Chen; Fuxiang Chen
Journal:  J Nanobiotechnology       Date:  2021-08-28       Impact factor: 10.435

6.  Chemopreventive efficacy of salvianolic acid B phospholipid complex loaded nanoparticles against experimental oral carcinogenesis: implication of sustained drug release.

Authors:  Wei Liu; Zengtong Zhou; Laikuan Zhu; Hongquan Li; Lan Wu
Journal:  Ann Transl Med       Date:  2022-03

Review 7.  Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents.

Authors:  Bilin Xu; Zhiliang Li; Ting Zeng; Jianfeng Zhan; Shuzhen Wang; Chi-Tang Ho; Shiming Li
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.411

8.  Long non-coding RNA ELDR enhances oral cancer growth by promoting ILF3-cyclin E1 signaling.

Authors:  Subhayan Sur; Hiroshi Nakanishi; Robert Steele; Dapeng Zhang; Mark A Varvares; Ratna B Ray
Journal:  EMBO Rep       Date:  2020-10-12       Impact factor: 9.071

9.  Momordicine-I, a Bitter Melon Bioactive Metabolite, Displays Anti-Tumor Activity in Head and Neck Cancer Involving c-Met and Downstream Signaling.

Authors:  Subhayan Sur; Robert Steele; T Scott Isbell; Kalyan Nagulapalli Venkata; Mostafa E Rateb; Ratna B Ray
Journal:  Cancers (Basel)       Date:  2021-03-21       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.